Patients with CRSwNP experience a high symptom burden and reduced quality of life (QoL)1,2
- Decreased sense
- Runny nose
- Nasal discharge
EAR AND FACIAL SYMPTOMS
- Facial pain
- Facial pressure
- Ear pain
- Ear fullness
- Difficulty falling/
- Waking up tired
- Reduced concentration
- Reduced productivity
- Frustrated, restless,
CRSwNP can remain uncontrolled in patients on standard-of-care therapies, which can lead to multiple sino-nasal surgeries and cycles of oral corticosteroid use1,3,4
of patients enrolled in DUPIXENT trials had a history of prior SCS use1
of patients enrolled in DUPIXENT clinical trials had a history of ≥1 prior surgery1
DUPIXENT TARGETS UPPER AND LOWER AIRWAY INFLAMMATION IN CRSwNP AND ASTHMA
DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling, two cytokines that contribute to underlying Type 2 inflammation in CRSwNP1,5,a
CRSwNP is predominantly characterized by Type 2 inflammation of the nose and paranasal sinuses and is frequently associated with comorbidities of the lower airway4-7
CRSwNP Lower airway
- aThe mechanism of dupilumab action in asthma has not been established.
DUPIXENT is indicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.
- CRSwNP, chronic rhinosinusitis with nasal polyposis; SCS, systemic corticosteroid.